BostonGene, a leading provider of artificial intelligence (AI)-enabled molecular and immune profiling solutions, is pleased to announce an immuno-oncology focused research collaboration with Takeda. The partnership aims to advance clinical solutions and improve patient outcomes by identifying key molecular drivers and predictive markers of treatment response and adverse events.
Takeda will utilize BostonGene’s AI-based multi-omics platform in early-stage clinical trials to enhance clinical trial design, improve indication selection, and identify biomarkers of response and toxicity. BostoGene will perform advanced multi-omics analysis using its proprietary analysis platform based on clinical and laboratory data provided by Takeda. In addition, BostonGene will perform bioinformatics analysis of flow cytometry, RNA sequencing, and proteomics data.
“We are pleased to partner with BostonGene to advance oncology research and development using cutting-edge technology,” said PK Morrow, MD, Head of Takeda’s Oncology Unit. “Through this collaboration, we hope to leverage data and AI to gain earlier insights into the biology and mechanisms of therapeutic drugs. This data will help us better understand the potential of therapeutics in specific patient populations, ultimately contributing to the development of cancer treatments that patients want.”
Also Read: Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
“We are excited about our research collaboration with Takeda,” said Nathan Fowler, M.D., Chief Medical Officer of BostonGene. ” Our state-of-the-art multi-omics analysis will significantly improve the patient selection process and identify key mechanistic signatures associated with response, advancing the development of innovative therapies.”
BostonGene is a company that combines strengths in technology and biology to advance and personalize cancer care. Founded in 2015, BostonGene is committed to continuously advancing innovation to improve cancer patient care and advance research and drug development. Using our AI-driven multi-omics analytics platform, we digitize and comprehensively characterize the molecular profile of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer libraries and advanced bioanalytics enable the discovery and targeting of multi-parameter signatures, which we then match to relevant indications for pharmaceutical companies to recommend the most effective treatments for patients.
SOURCE: Businesswire